GlassScriptPhysician profile
Benjamin F Call
NPI 1346236213
$4,621.31
in general payments reported to CMS, 2019-2025
25 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $175 · 2021: $493 · 2022: $436 · 2023: $794 · 2024: $1,626 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187 · Travel and Lodging: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.80 |
| Travel and Lodging | $148.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $762.16 | 2024-2025 | Micra, Attain Command + Surevalve, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $757.84 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $469.61 | 2021-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $457.57 | 2020-2025 | Mitraclip, Cardiomems, Ensite |
| Pfizer INC. | $387.02 | 2020-2025 | |
| Boston Scientific Corporation | $360.54 | 2019-2025 | Accolade Sr, Watchman Flx, Watchman Access System |
| Impulse Dynamics (USA) INC. | $159.78 | 2024-2025 | Optimizer |
| Amgen INC. | $129.48 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $128.24 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $122.20 | 2023-2024 | Inpefa |
| Cvrx, INC. | $121.17 | 2021-2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $119.61 | 2023-2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $115.09 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $102.34 | 2020-2023 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.79 | 2023-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.62 | 2021-2024 | Lifevest |
| Abiomed | $63.05 | 2024 | Impella |
| Irhythm Technologies, INC. | $50.78 | 2021-2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $35.79 | 2021 | |
| Esperion Therapeutics, INC. | $34.71 | 2021 | |
| Scpharmaceuticals INC. | $25.68 | 2025 | |
| Merck Sharp & Dohme LLC | $22.79 | 2025 | Verquvo |
| Siemens Medical Solutions USA, INC. | $19.64 | 2024 | Acuson Origin Diagnostic Ultrasound System |
| Regeneron Healthcare Solutions, INC. | $11.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.